Zerviate FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2020.
FDA Approved: Yes (First approved May 30, 2017)
Brand name: Zerviate
Generic name: cetirizine hydrochloride
Dosage form: Ophthalmic Solution
Company: Nicox Ophthalmics, Inc.
Treatment for: Conjunctivitis, Allergic
Zerviate (cetirizine hydrochloride) is a histamine-1 (H1) receptor antagonist ophthalmic formulation for the treatment of ocular itching associated with allergic conjunctivitis.
The approval of Zerviate was based on efficacy data from three randomized, double-masked, placebo-controlled clinical trials in patients with a history of allergic conjunctivitis. Zerviate demonstrated statistically and clinically significantly less ocular itching compared to vehicle at 15 minutes and 8 hours after treatment.
Zerviate is an ophthalmic solution administered as a single drop into the affected eye twice daily. Common side effects include eye redness (ocular hyperemia), pain at instillation site, and reduced clarity of vision (visual acuity).
Development Timeline for Zerviate
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.